Heinz‐Josef Lenz

University of Southern California (US)

Research Areas

Discover Papers by Heinz‐Josef Lenz

Access 250+ million papers and cite this researcher's work with AI assistance

Try AnswerThis Free →

H-index

109

Publications

1939

Citations

59592

i10-index

568

Publications & Citations Over Time

Top Cited Publications

Want to find and read papers by this researcher? AnswerThis gives you instant access.

Title	Year	Citations
Regorafenib monotherapy for previously treated met...	2012	2893
Nivolumab in patients with metastatic DNA mismatch...	2017	2829
Durable Clinical Benefit With Nivolumab Plus Ipili...	2018	2080
CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activa...	2017	1620
Randomized Trial of TAS-102 for Refractory Metasta...	2015	1429
Colorectal cancer	2010	1407
EPIC: Phase III Trial of Cetuximab Plus Irinotecan...	2008	946
Effect of First-Line Chemotherapy Combined With Ce...	2017	899
Prognostic and predictive value of primary tumour ...	2017	840
Fluorouracil, Leucovorin, and Irinotecan Plus Cetu...	2015	791

Publications

1.
Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
Year: 2012Citations: 2893DOI: 10.1016/s0140-6736(12)61900-x
2.
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
Year: 2017Citations: 2829DOI: 10.1016/s1470-2045(17)30422-9
3.
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer
Year: 2018Citations: 2080DOI: 10.1200/jco.2017.76.9901
4.
CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation – A target for novel cancer therapy
Year: 2017Citations: 1620DOI: 10.1016/j.ctrv.2017.11.007
5.
Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer
Year: 2015Citations: 1429DOI: 10.1056/nejmoa1414325
6.
Colorectal cancer
Year: 2010Citations: 1407DOI: 10.1016/s0140-6736(10)60353-4
7.
EPIC: Phase III Trial of Cetuximab Plus Irinotecan After Fluoropyrimidine and Oxaliplatin Failure in Patients With Metastatic Colorectal Cancer
Year: 2008Citations: 946DOI: 10.1200/jco.2007.13.1193
8.
Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer
Year: 2017Citations: 899DOI: 10.1001/jama.2017.7105
9.
Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials
Year: 2017Citations: 840DOI: 10.1093/annonc/mdx175
10.
Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Treatment and RAS Mutations in Colorectal Cancer
Year: 2015Citations: 791DOI: 10.1200/jco.2014.59.4812

About Heinz‐Josef Lenz

Heinz‐Josef Lenz is a researcher with 1939 publications and 59592 citations. They are affiliated with University of Southern California. Their research focuses on . With an h-index of 109, they are among the top researchers in their field.

Citation Distribution

Distribution of citations across publications

Research Smarter

AnswerThis uses AI to help you search, understand, and cite research from Heinz‐Josef Lenz and 250M+ other papers.

AI-powered research assistance
Automatic citations and references
Advanced academic writing tools

Research Area Breakdown

Publication Types

Publication type data not available

Impact Metrics Over Time

Citations per publication by year